press releases
IDRI in the news
publications
|  |
Publications
Adjuvants
Baldwin S.L., Fox C.B., Pallansch M.A., Coler R.N., Reed S.G., Friede M. (2011). Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions, Vaccine 29; 644-649.
Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev, 2011, 239(1): 178-196.
Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Freide M, Vedvick TS, Reed SG. Development and characterization of a synthetic Glucopyranosyl Lipid A system as a vaccine adjuvant. Plos One, 2011, 6(1): e16333. doi:10.1371/journal.pone.0016333
PMCID — PMC3027669
Carter D, Reed SG. Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS. 2010 Sep;5(5):409-13. Review.
Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem. 2010;53:303-21.
Fox, C., S Lin, S Sivananthan, T Dutill, Forseth, K, S Reed, T Vedvick. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. Pharmaceutical Development and Technology, 2010, 1-9 Early Online.
Fox CB, Dutill TS, Chesko J, Anderson RC, Reed SG, Vedvick TS. Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations containing CpG ODNs, Biopharm International, 2010, October Supplement:14-19.
R. C. Anderson, C. B. Fox, T. S. Dutill, N. Shaverdian, T. L. Evers, G. R. Poshusta, J. Chesko, R. N. Coler, M. Friede, S. G. Reed, T. S. Vedvick, Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations, Colloids and surfaces B: Biointerfaces 2010 Jan 1;75(1): 123-32. PMCID — In Process
Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER. Protection against intestinal amebiasis by a recombinant vaccine is transferrable by T cells and mediated by gamma interferon. Infec Immun. 2009 Sep;77(9):3909-18. Epub 2009 Jun 29. PMCID: PMC2738017
Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development Trends in Immunology 2009 Jan 30 (1):23-32. PMID: 19059004.
Fox, C.B., R.C. Anderson, T.S. Dutill, Y. Goto, S.G. Reed, and T.S. Vedvick. 2008. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids and Surfaces B: Biointerfaces 65:98—105. PMID: 18440205.
Persing, D.H., R.N. Coler, M.J. Lacy, D.A. Johnson, J.R. Baldridge, R.M. Hershberg, and S.G. Reed. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:S32-S37.
Chlamydia
Coler R.N., A. Bhatia, J.F. Maisonneuve, P. Probst, B. Barth, P. Ovendale, H. Fang, M. Alderson, Y. Lobet, J. Cohen, P. Mettens, and S.G. Reed. 2009. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol. 55:258-270. PMCID: PMC2776724
Influenza
Coler R.N., Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Xiuhua L, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. 2010.PLOS ONE. 5(10): e13677.doi:10/1371/journal.pone.0013677
PMCID: PMC2965144
Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., Mompoint F., Vedvick T., Bertholet S., Coler R.N., and Reed S.G. (2009). Enhanced humoral and type 1 immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27; 5956-5963.
Leishmaniasis
Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF, Vidal SEZ, Vedvick TS, Howard RF, and Reed SG (2011). KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis. Clinical and Vaccine Immunology 18:7; 1118-1124.
PMCID: In Process.
Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. (2011). A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. April 27; 29(19):3531-7. Epub 2011 Mar 15.
Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of Ex Vivo Human Immune Response against Candidate Antigens for a Visceral Leishmaniasis Vaccine. Am J Trop Med Hyg., 82(5), 2010, 808-13 PMCID: PMC2861380
Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves Fabiana P, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 28 (2010) 7427-7435
Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, RS de Jesus, Goto Y, Guderian J, Howard RF, Reed SG. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28 (2010) 3333-40. PMCID: PMC2874835
Santarém N, Silvestre R, Cardoso L, Schallig H, Reed SG, Cordeiro-da-Silva A. Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis. J Clin Microbiol. 2010 May;48(5):1866-74. Epub 2010 Feb 17. PMCID: PMC2863945
Raman V, Bhatia A, Picone A, Whittle J, Bailor H, O'Donnell J, Pattabhi S, Guderian J A, Mohomath R, Duthie M S, Reed S G. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. Journal of Immunology. 2010;185;1701-1710. PMCID PMC3109724
Pattabhi S, Whittle J, Mohamath R, El-Safi S, Moulton GG, Guderian J, Colombara D, Abdoon AO, Mukhtar MM, Mondal D, Esfandiari J, Kumar S, Chun P, Reed SG, Bhatia A. Design, Development and Evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLOS Neg Trop Dis 2010 Sept; 4(9): e822
PMCID PMC29339046
Nascimento E, Fernandes D, Viera E, Campos-Neto A, Ashman J, Alves F, Coler R, Bogatzki L, Kahn S, Beckmann AM, Pine S, Cowgill K, Reed S, Piazza F. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28 (2010) 6581-6587. PMID: 20703747
Goto Y, Reed S. Antigen discovery for serological diagnosis of visceral leishmaniasis. Current Chemical Biology 2010 (4) 225-230.
Goto Y, Carter D, Guderian J, Inoue N, Kawazu S-I, Reed S. Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotes. Infection and Immunity May 2010 vol. 78, no. 5 p. 2138-2145. PMCID PMC2863543
Velez I, Gilchrist K, Martinez S, Ramirez-Pineda J, Ashman J, Alves F, Coler R, Bogatzki L, Kahn S, Beckmann AM, Pine S, Cowgill K, Reed S, Piazza F. Safety and immunogeneicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28 (2009) 329-337. PMID: 19879995
Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, Coler RN, Vedvick TS, Reed SG. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009 Nov 23;27 (50): 7036-45
PMCID: PMC2783536
Goto Y, Bhatia A, Raman VS, Vidal SE, Bertholet S, Coler RN, Howard RF, Reed SG. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 27 (2009) 2884-2890.
PMCID: PMC2694840
Goto Y, Howard RF, Bhatia A, Trigo J, Nakatani M, Netto EM, Reed SG. Distinct antigen recognition patterns during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol. 2009 Mar 23;160(3-4):215-20. PMID: 19059724.
PMCID: PMC2947490
Mehta, Sanjay R.; Huang, Robert; Yang, Meng; Zhang, Xing-Quan; Kolli, Bala; Chang, Kwang-Poo; Hoffman, Robert M.; Goto, Yasuyuki; badaro, Robert; Schooley, Robert T. Dec. 2008. Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery. Clinical and Vaccine Immunology. Vol. 15, No.12, 1764-1770.
PMCID PMC2593180
Miret, J., E. Nascimento, W. Sampaio, J.C. Franca, R.T. Fujiwara, A. Vale, E. Santos Dias, E. Vieira, R. T. da Costa, W. Mayrink, A. Campos-Neto, S.G. Reed. 2008. Evaluation of an immunochemotherapeutic Q1 protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis. Vaccine. 2008 Mar 17; 26(12):1585-94. Epub 2008 Feb 4. PMID: 18328956
Vedvick, T.S., Carter L., Moulton, G., Goto, Y., Bertholet, S., Reed S.G., Carter, D. 2008. An improved manufacturing process for a recombinant polyprotein vaccine. Biopharm International. Supplement January, 14-22.
Goto, Y., L.Y. Bogatzki, S. Bertholet, R.N. Coler, and S.G. Reed. 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine. 25:7450-7458.
PMCID: PMC2077354
Coler, R.N., Y. Goto, L. Bogatzki, V. Raman, and S.G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75:4648-4654.
PMCID: PMC1951162
Darrah, P.A., D.T. Patel, P.M. De Luca, R.W. Lindsay, D.F. Davey, B.J. Flynn, S.T. Hoff, P. Andersen, S.G. Reed, S.L. Morris, M. Roederer, and R.A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
Goto Y, Coler RN, Reed SG. Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun. 2007 Feb; 75(2):846-51.
PMCID: PMC1828517
Badaro, R., I. Lobo, A. Munõs, E.M. Netto, F. Modabber, A. Campos-Neto, R.N. Coler and S.G. Reed. 2006. Immunotherapy for Drug Refractory Mucosal Leishmaniasis. J. Inf. Dis. 194:1151-1159.
Goto, Y, R.N. Coler, J. Guderian, R. Mohamath, and S.G. Reed. 2006. Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect. Immun. July; 74(7):3939-3945.
PMCID: PMC1489730
Fujiwara, R.T., A.M. Vale, J.C. França da Silva, R.T. da Costa, J.D.S. Quetz, O.A. Martins Filho, A.B. Reis, R. Corrêa Oliveira, G.L. Machado-Coelho, L.L. Bueno, J.M. Bethony, G. Frank, E. Nascimento, O. Genaro, W. Mayrink, S. Reed, and A. Campos-Neto. 2005. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res. 36:827—838.
Coler, R.N., and S.G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. May; 21 (5):244-249.
Reed, S.G., R.N. Coler, and A. Campos-Neto. 2003. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev. Vaccines 2:239-252.
Chang, K.P., S.G. Reed, B.S. McGwire, and L. Soong. 2003. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop. 85:375-390.
Zerpa, O., M. Ulrich, M. Benitez, C. Avila, V. Rodriguez, M. Centeno, D. Belizario, S.G. Reed, and J. Convit. 2002. Epidemiological and immunological aspects of human visceral leishmaniasis on Margarita Island, Venezuela. Mem. Inst. Oswaldo Cruz 97:1079-1083.
Braz, R.F.S., E.T. Nascimento, D.R.A. Martins, M.E. Wilson, R.D. Pearson, S.G. Reed, and S.M.B. Jeronimo. 2002. The sensitivity and specificity of Leishmania chagasi recombinant k39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am. Journ. Trop. Med. Hyg. 67:344-348.
Skeiky, Y.A.W., R.N. Coler, M. Brannon, E. Stromberg, K. Greeson, R.T. Crane, A. Campos-Neto, and S.G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant. Vaccine. 20(27-28):3292.
Coler, R.N., Y.A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. Cornellison, F. Modabber, A. Campos-Neto, and S.G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
PMCID: PMC128156
Campos-Neto, A., J.R. Webb, K. Greeson, R.N. Coler, Y.A.W. Skeiky, and S.G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. and Immun. 70:2828-2836.
PMCID: PMC128002
Borges, M.M., A. Campos-Neto, P. Sleath, K.H. Grabstein, P.J. Morrissey, Y.A.W. Skeiky, and S.G. Reed. 2001. Potent Stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein. Infect. Immun. 69:5270-5277.
Campos-Neto, A., R. Porrozzi, K. Greeson, R.N. Coler, J.R. Webb, Y.A.W. Skeiky, S.G. Reed, and G. Grimaldi, Jr. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of human disease. Infect. and Immun. 69:4103-4108
PMCID: PMC98475
Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M.A. Moga, Y.A.W. Skeiky, A. Campos-Neto, S.G. Reed, R.A. Seder and D. Sacks. 2001. The potency and durability of dna- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
Probst, P., E. Stromberg, H.W. Ghalib, M. Mozel, R. Badaro, S.G. Reed, and J.R. Webb. 2001. Identification and characterization of T cell stimulating antigens from Leishmania by CD4 T cell expression cloning. J. Immunol. 166:498-505.
Reed SG. 2001. Leishmaniasis vaccination: targeting the source of infection. J. Exp Med. 194:F7-F9.
PMCID: PMC2193470
Medeiros, I.M., S.G. Reed, A. Castelo, and R. Salomao. 2000. Circulating levels of sTNFR and discrepancy between cytotoxicity and immnoreactivity of TNF-α in patients with visceral leishmaniasis. Clin. Microbiol. Infect. 6:34-37.
Bhatia, A., N.S. Daifalla, S. Jen, R. Badaro, S.G. Reed, and Y.A.W. Skeiky. 1999. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol. Biochem. Parasitol 102:249-261.
Skeiky, Y.A.W., M. Kennedy, D. Kaufman, M.M. Borges, J.A. Guderian, J.K. Scholler, P.J. Ovendale, K.S. Picha, P.J. Morrissey, K.H. Grabstein, A. Campos-Neto, and S.G. Reed. 1998. LeIF: A recombinant Leishmania protein that induces an IL-12 mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
Ozensoy, S., Y. Ozbel, N. Turgay, M. Ziya Alkan, K. Gul, A. Gilman-Sachs, K.-P. Chang, S.G. Reed, and M. Ali Ozcel. 1998. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. Am. J. Trop. Med. Hyg. 59:363-369.
Webb, J.R., A. Campos-Neto, P.J. Ovendale, T.I. Martin, E.J. Stromberg, R. Badaro, and S.G. Reed. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by a multi-copy gene family. Infect. and Immun. 66:3279-3289.
Webb, J.R., A. Campos-Neto, Y.A.W. Skeiky, and S.G. Reed. 1997. Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol. Biochem. Parasitol. 89:179-193.
Skeiky, Y.A.W., D.R. Benson, J.L.M. Costa, R. Badaro and S.G. Reed. 1997. Association of Leishmania heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis. Infect. and Immun. 65:5368-5370.
Probst, P., Y.A.W. Skeiky, M. Steeves, A. Gervassi, K.H. Grabstein, and S.G. Reed. 1997. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor- production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27:2634-2642.
Sundar, S., S.G. Reed, S. Sharma, A. Mehrotra, and H.W. Murray. 1997. Circulating T Helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522-525.
Webb, J.R., D. Kaufmann, A.Campos-Neto, and S.G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.
Campbell, K.A., P.J. Ovendale, M.K. Kennedy, W.C. Fanslow, S.G. Reed, and C.R. Maliszewski. 1996. CD40 ligand is required to generate a protective cell-mediated immune response to Leishmania major. Immunity 4:283-289.
Badaro, R., D.R. Benson, M. C. Eulalio, M. Freire, S. Cunha, E.M. Netto, D. Pedral-Sampaio, C. Madureira, J.M. Burns, Jr., J.R. David, and S.G. Reed. 1996. rK39: A cloned antigen of Leishmania chagasi that both detects and predicts active visceral leishmaniasis. J. Infect. Dis. 173:758-762.
Singh, S., A. Gilman-Sachs, K.-P. Chang and S.G. Reed. 1995. Diagnostic and prognostic value of rK39 antigen in Indian leishmaniasis. J. Parasitol. 81:1000-1003.
Campos-Neto, A., L. Soong, J.L. Cordova, D. Sant'Angelo, Y.A.W. Skeiky, N.H. Ruddle, S.G. Reed, C. Janeway, Jr., and D. McMahon-Pratt. 1995. Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J. Exp. Med. 182:1423-1433.
Skeiky, Y.A.W., D.R. Benson, J.A. Guderian, J.A. Whittle, O. Bacelar, E.M. Carvalho, and S.R. Reed. 1995. Immune responses of leishmaniasis patients to Leishmania and human heat shock proteins. Infect. and Immun. 63:4105-4114.
Dillon, D.C., C.H. Day, J.A. Whittle, A.J. Magill, and S.G. Reed. 1995. Characterization of a Leishmania tropica antigen that detects immune responses in Desert Storm viscerotropic leishmaniasis patients. Proc. Nat. Acad. Sci. USA 92:7981-7985.
Cunha, S., M. Freire, C. Eulalio, J. Critosvao, E. Netto, W.D. Johnson, Jr., S.G. Reed, and R. Badaro. 1995. Visceral leishmaniasis in a new ecological niche near a major metropolitan area of Brazil. Trans. Roy. Soc. Trop. Med. Hyg. 89:155-158.
Ghalib, H.W., J.A. Whittle, M. Kubin, F.A. Hashim, A.M. El-Hassan, K.H. Grabstein, G. Trinchieri, and S.G. Reed. 1995. IL-12 enhances Th1 type responses in human Leishmania donovani infections. J. Immunol. 154:4623-4629.
Skeiky, Y.A.W., J.A. Guderian, D.R. Benson, O. Bacelar, E.M. Carvalho, M. Kubin, R. Badaro, G. Trinchieri, and S.G. Reed. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. J. Exp. Med. 181:1527-1537.
Skeiky, Y.A.W., Benson, D.R., Elwasila, M., Badaro, R., Burns, J.M., and Reed, S.G. 1994. Shared antigens between Leishmania and Trypanosoma cruzi: characterization of the Leishmania chagasi acidic ribosomal protein PO. Infect. and Immun. 62:1643-1651.
Leprosy
Duthie MS, Hay MN, Rada EM, Convit J, Ito L, Oyafuso LKM, Manini MIP, Goulart IMB, Lobato J, Goulart LR, Carter D, Reed SG. (2011) Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as a recurrence prognostic markers. Eur J Clin Microbial Infect Dis. DOI 10.1007/s10096-011-1221-2
Duthie MS, Truman RW, Goto W, O'Donnell J, Hay MN, Spencer JS, Carter D, Reed SG. Insight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos. Clin Vaccine Immunol. 2011 Feb;18(2):254-9. Epub 2010 Dec 22. PMCID: PMC3067361
Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, Duthie MS. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis. 2011 Jan 26;11(1):26. PMCID: PMC3040138
Duthie MS, Hay MH, Morales CZ, Carter L, Mohamath R, Ito L, Oyafuso LKM, Manini MIP, Balagon MV, Tan EV, Saunderson PR, Reed SG, Cater D. Rational design and evaluation of a multiepitope chimeric fusion protein and the potential for leprosy diagnosis. Clin Vaccine Immun. Feb 2010 (17):2. 298-03.
PMCID: PMC2815528
Raman VS, O'Donnell J, Bailor HR, Goto W, Lahiri R, Gillis TP, Reed SG, Duthie MS. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infec Immun. Dec 2009 (77):12. 5623-30.
Duthie MS, Goto W, Ireton GC, Reece ST, Sampaio LH, Grassi AB, Sousa AL, Martelli CM, Stefani MM, Reed SG. Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol. 2008 Nov;15(11):1659-65.
PMCID: PMC2583521
Duthie MS, Ireton GC, Kanaujia GV, Goto W, Liang H, Bhatia A, Busceti JM, Macdonald M, Neupane KD, Ranjit C, Sapkota BR, Balagon M, Esfandiari J, Carter D, Reed SG. Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol. 2008 Oct;15(10):1590-7.
PMCID: PMC2565937
Duthie, M.S., W. Goto, G.C. Ireton, S.T. Reece, L.P. Cardoso, C.M. Martelli, M.M. Stefani, M. Nakatani, R.C. de Jesus, E.M. Netto, M.V. Balagon, E. Tan, R.H. Gelber, Y. Maeda, M. Makino, D. Hoft, and S.G. Reed. 2007. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol. Nov; 14(11):1400-1408.
PMCID: PMC2168166
Duthie, M.S., S.T. Reece, R. Lahiri, W. Goto, V.S. Raman, J. Kaplan, G.C. Ireton, S. Bertholet, T.P. Gillis, J.L. Krahenbuhl, and S.G. Reed. 2007. Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear. Infect Immun. Nov; 75(11):5290-5297.
PMCID: PMC2168264
Reece, S.T. G. Ireton, R. Mohamath, J. Guderian, W. Goto, R. Gelber, N. Groathouse, J. Spencer, P. Brennan, and S.G. Reed. 2006. ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clin. Vaccine Immunol. March; 13(3):333-340.
PMCID: PMC1391965
Malaria
Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, Reed SG, Chitnis CE, Carter D. 2011. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Science Translational Medicine, 3, 93ra69.
Lousada-Dietrich S, Jogdand P, Jepsen S, Pinto V, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RH, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M. 2011. A synthetic agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 — A GLURP — MSP3 fusion protein malaria vaccine candidate. Vaccine, 29:3284-3292.
Coler, R. N., Carter, D., Friede, M. and Reed, S. G. 2009. Adjuvants for malaria vaccines. Parasite Immunology, 31: 520—528. doi: 10.1111/j.1365-3024.2009.01142.x
Miscellaneous
Chesko J, Anderson R, Fox C, Kalvodova L, Dutill T, Reed S, Vedvick TS. Nonionic surfactants formulated into drug and vaccine delivery systems. Non-Ionic Surfactants ed. Pierce L Wendt and Demario S Hoysted (2009) 177-197.
Fox C.B. Squalene Emulsions for Parenteral Vaccine and Drug Delivery. Molecules. 2009; 14(9):3286-3312.
Reed, S.G., and A. Campos-Neto. 2003. Vaccines for parasitic and bacterial diseases. In: Current Opinions in Immunology 15:456-460.
Day CH, Fanger GR, Retter MW, Hylander BL, Penetrante RB, Houghton RL, Zhang X, McNeill PD, Filho AM, Nolasco M, Badaro R, Cheever MA, Reed SG, Dillon DC, Watanabe Y. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene. 2002 Oct 10;21(46):7114-20.
Lodes MJ, Mohamath R, Reynolds LD, McNeill P, Kolbert CP, Bruinsma ES, Benson DR, Hofmeister E, Reed SG, Houghton RL, Persing DH. Serodiagnosis of human granulyoctic ehrlichiosis by using novel combinations of immunoreactive recombinant proteins. J Clin Microbiol. 2001. Jul;39(7):2466-76. PMCID: PMC88172
Lodes MJ, Houghton RL, Bruinsma ES, Mohamath R, Reynolds LD, Benson DR, Krause PJ, Reed SG, Persing DH. Serological expression cloning of novel immunoreactive antigens of Babesia microti. Infect Immun. 2000 May;68(5) :2783-90. PMCID: PMC97488
Lewinsohn, D.M., T. Tough-Bement, D.H. Lynch, K.H. Grabstein, S.G. Reed, and M.R. Alderson. 1998. Human purified protein derivative-specific CD4+ T cells utilize both CD95-dependent and CD95-independent cytolytic mechanisms. J. Immunol. 160:2374-2379.
Akridge, R.E., and S.G. Reed. 1996. Interleukin-12 decreases HIV-1 replication in human macrophages reconstituted with autologous PBMC. J. Infect. Dis. 173:559-564.
Akridge, R.E., L.M. Keiko, and S.G. Reed. 1994. Interleukin-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J. Immunol. 153:5782-5789.
Reed, S.G. 1993. Macrophage activation and inactivation in protozoal infections. In: Hemopoietic Growth Factors and Mononuclear Phagocytes. R. van Furth, editor, Basel, Karger, pp 98-110.
Trypansoma Cruzi
Houghton RL, Stevens YY, Hjerrild K, Guderian J, Okamto M, Kabir M, Reed SG, Leiby DA, Morrow WJ, Lorca M, Raychaudhuri S. Lateral flow immunoassay for diagnosis of Trypansoma cruzi infection with high correlation to the radioimmunoprecipitation assay. Clin Vaccine Immunol. 2009 Apr; 16(4):515-20. Epub 2009 Feb 11. PMCID: PMC2668284
Goto Y, Carter D, Reed SG. Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun. 2008 Sep;76(9):3967-74.
PMCID: PMC2519453
Goto Y, Carter D, Reed SG. Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun. 2008 Sep;76(9):3967-74.
Duthie MS, Kahn M, Zakayan A, White M, Kahn SJ. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol. 2007 Aug;14(8):1005-12. Epub 2007 May 30. PMID: 17538117
Duthie MS, Kahn SJ. During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. Immunology. 2006 Nov;119(3):355-61. PMID: 16879622
Duthie MS, Kahn SJ. NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection. Int Immunol. 2005 May;17(5):607-13. Epub 2005 Mar 31. PMID: 15802307
Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection. Infect Immun. 2005 Mar 73(3):1890-4. PMID: 15731095
PMCID: PMC1064964
Duthie MS, Cetron MS, Van Voorhis WC, Kahn SJ. Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes. Acta Trop. 2005 Mar 93(3):317-29. PMID: 15725381
Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun. 2005 Jan;73(1):181-92.PMID: 15618153
PMCID: PMC538963
Campos-Neto, A, I. Suffia, K.A. Cavassani, S. Jen, K. Greeson, P. Ovendale, J.S. Silva, S.G. Reed, and Y.A. Skeiky. 2003. Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family trypanosomatidae. Infect. Immun. 71:5065-5076.
PMCID: PMC187365
Ferreira, A.W., Z.R. Belem, E.A. Lemos, S.G. Reed, and A. Campos-Neto. 2001. LemEnzyme-linked immunosorbent assay for serological diagnosis of Chagas' Disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. J. Clin. Microbiol. 39:4390-4395.
Duthie MS, Kahn SJ. Treatment with alpha-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. J Immunol. 2002 Jun 1; 168(11):5778-85. PMID: 12023379
Reed, S.G. 1998. Immunology of Trypanosoma cruzi infections. In: Chemical Immunology, Immunology of Intracellular Parasitism. 70:124-143.
Ismail, S.O., W. Paramchuk, Y.A.W. Skeiky, S.G. Reed, A. Bhatia, and L. Gedamu. 1997. Molecular cloning and characterization of two iron superoxide dismutase cDNAs from Trypanosoma cruzi. Mol. Biochem. Parasitol. 86:187-197.
Cardillo, F., J.C. Voltarelli, S.G. Reed, and J.S. Silva. 1996. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin-10: Role of NK cells. Infect. and Immun. 64:128-134.
Reed, S.G., C.E. Brownell, D.M. Russo, J.S. Silva, K.H. Grabstein, and P.J. Morrissey. 1994. Interleukin-10 mediates susceptibility to Trypanosoma cruzi infection. J. Immunol. 153:3135-3140.
Skeiky, Y.A.W., Benson, D.R., Elwasila, M., Badaro, R., Burns, J.M., and Reed, S.G. 1994. Shared antigens between Leishmania and Trypanosoma cruzi: characterization of the Leishmania chagasi acidic ribosomal protein PO. Infect. and Immun. 62:1643-1651.
Tuberculosis
Carroll P, Faray-Kele MC, Parish T. Identifying vulnerable pathways in Mtb by using a knockdown approach. (2011) Applied and Environmental Microbiology 77;14:5040-5043.
Roberts, Gretta, Vadrevu, Indumathi S, Madiraju, Murty V, Parish, Tanya. (2011) Control of CydB and GltA1 Expression by the SenX3 RegX3 Two Component Regulatory System of Mtb, Plos One6(6): e21090. doi:10.1371/journal.pone.0021090
Muttucumaru DGN, Smith DA, McMinn E, Reese V, Coler RN, Parish T. (2011) Mycobacterium tuberculosis Rv0198c, a putative matrix metalloprotease is involved in pathogenicity, Tuberculosis, doi. 10. 10/16/j.tube.2010.11.010
Bertholet S., Ireton G, Ordway D, Windish HP, Pine SO, Kahn M, Phan T, Orme I, Vedvick TS, Baldwin SL, Coler RN, Reed SG. 2010 A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobaterium tuberculosis. Science Translational Medicine 2:53 53ra74 PMCID: PMC3110937 [Available on 2011/10/13]
Ireton GC, Greenwald R, Liang H, Esfandiari J, Lyashchenko KP, Reed SG. Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin Vaccine Immunol. 2010 Oct; 17(10): 1539-47. Epub 2010 Aug 18. PMCID: PMC2952993
T.R. Ioerger, Y. Feng, K. Ganesula, X. Chen, K.M. Dobos, S. Fortune, W.R. Jacobs, V. Mizrahi, T. Parish, E. Rubin C. Sassetti and J.C. Sacchettini. 2010. Variation among genome sequences of H37Rv strains of M. tuberculosis from multiple laboratories. J. Bacteriol. 192:3645-3653.
N. Andreu, A. Zelmer, T. Fletcher, P.T. Elkington, T.H. Ward, J. Ripoll, T. Parish, G.J. Bancroft, U. Schaible, B.D. Robertson and S. Wiles. Optimisation of bioluminescent reporters for use with mycobacteria PLoS One. 5(5): e10777. PMCID: PMC2875389
A.C. Brown, M. Eberl, D.C. Crick, H. Jomaa and T. Parish. 2010. The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally-regulated by Dxs activity. J. Bacteriol. 192: 2424-2433 PMCID: PMC2863480
Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T. Sensitive Detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS ONE 5(3): e9823. doi:10.1371/journal.pone.0009823
R. Goude, A. G. Amin, D. Chatterjee, and T. Parish. The Arabinosyltransferase EmbC Is Inhibited by Ethambutol in Mycobacterium tuberculosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2009, Vol. 53, No. 10: 4138—4146.
Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN. (2009) Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine. May 18; 27 (23) : 3063-71. Epub 2009 Mar 26. PMCID: PMC2743149
Steven G. Reed, Rhea N. Coler, Wilfried Dalemans, Esterlina V. Tan, Eduardo C. DeLa Cruz, Randall J. Basaraba, Ian M. Orme, Yasir A. W. Skeiky, Mark R. Alderson, Karen D. Cowgill, Jean-Paul Prieels, Rodolfo M. Abalos, Marie-Claude Dubois, Joe Cohen, Pascal Mettens, and Yves Lobet. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A. 2009 February 17; 106(7): 2301—2306. doi: 10.1073/pnas.0712077106.
PMCID: PMC2650151
Coler RN, Dillon DC, Skeiky YA, Kahn M, Orme IM, Lobet Y, Reed SG, Alderson MR. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine 2009 Jan 7; 27(2):223-33. PMCID: PMC2673800
Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008 Dec 1; 181(11):7948-57. PMID: 19017986
PMCID: PMC2586986
R. Goude and T. Parish. The Genetics of Cell Wall biosynthesis in Mycobacterium tuberculosis. Future Microbiology. 2008; 3(3): 299-313.
Keeler, E., M.D. Perkins, P. Small, C. Hanson, S.G. Reed, J. Cunningham, J.E. Aledort, L. Hillborne, M.E. Rafael, F. Girosi, and C. Dye. 2006. Reducing the global burden of tuberculosis: The contribution of improved diagnostics. Nature Nov 23;444 Suppl 1:49-57.
Tsenova, L., R. Harbacheuski, A.L. Moreira, E. Ellison, W. Dalemans, M.R. Alderson, B. Mathema, S.G. Reed, Y.A. Skeiky, and G. Kaplan. 2006. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect. Immun. 74:2392-2401.
Mukherjee S., S.S. Kashino, Y. Zhang, N. Daifalla, V. Rodrigues, Jr., S.G. Reed, and A. Campos-Neto. 2005. Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process. J. Immunol. 175: 5298—5305.
Irwin, S.M., A.A. Izzo, S.W. Dow, Y.A. Skeiky, S.G. Reed, M.R. Alderson, and I.M. Orme. 2005. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect. Immun. 73:5809-5816.
PMCID: PMC1231129
Skeiky, Y.A., M.R. Alderson, P.J. Ovendale, Y. Lobet, W. Dalemans, I.M. Orme, S.G. Reed, and A. Campos-Neto. 2005 Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine 23:3937-3745.
Reece, S.T., N. Stride, P. Ovendale, S.G. Reed, and A. Campos-Neto. 2005. Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs. Infect. Immun. 73:3301-3306.
PMCID: PMC1111880
Brandt, L., Y.A. Skeiky, M.R. Alderson, Y. Lobet, W. Dalemans, O.C. Turner, R.J. Basaraba, A.A. Izzo, T.M. Lasco, P.L. Chapman, S.G. Reed, and I.M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72:6622-6632.
Skeiky, Y.A., M.R. Alderson, P.J. Ovendale, J.A. Guderian, L. Brandt, D.C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I.M. Orme, and S.G. Reed. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172:7618-7628.
Mukherjee, S., N. Daifalla, Y. Zhang, J. Douglass, L. Brooks, T. Vedvick, R. Houghton, S.G. Reed, and A. Campos-Neto. 2004. Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice. Clin. Diagn. Lab. Immunol. 11:280-286.
PMCID: PMC371208
Liu, C., E. Flamoe, H.J. Chen, D. Carter, S.G. Reed, and A. Campos-Neto. 2004. Expression and purification of immunologically reactive DPPD, a recombinant Mycobacterium tuberculosis skin test antigen, using Mycobacterium smegmatis and Escherichia coli host cells. Can. J. Microbiol. 50:97-105.
Reed, S.G., M.R. Alderson, W. Dalemans, Y. Lobet, and Y.A. Skeiky. 2003. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb).83:213-219.
Campos-Neto, A., V. Rodrigues-Júnior, D.B. Pedral-Sampaio, E.M. Netto, P.J. Ovendale, R.N. Coler, Y.A.W. Skeiky, R. Badaró and S.G. Reed. 2001. Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein, as an alternative antigen for the Mantoux test. Tuberculosis 81:353-358.
Lodes, M.J., D.C. Dillon, R. Mohamath, C.H. Day, D.R. Benson, L.D. Reynolds, P. McNeill, Y.A.W. Skeiky, R. Badaro, D.H. Persing, S.G. Reed, and R.L. Houghton. 2001. Serological expression cloning and immunological evaluation of MTB48, a novel Mycobacterium tuberculosis antigen. J. Clin. Microbiol. 39:2485-2493.
Coler, R.N., A. Campos-Neto, P. Ovendale, F.H. Day, S.P. Fling, L. Zhu, N. Serbina, J.L. Flynn, S.G. Reed, and M.R. Alderson. 2001. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J. Immunol. 166:6227-6235.
Lewisohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, Grabstein KH, Alderson MR. Classically restricted human CD8+ T lymphocytes derived from Mtb infected cells: definition of antigenic specificity. J Immunol. 2001 Jan 1;166(1):439-46.
Lewisohn DM, Briden Al, Reed SG, Grabstein KH, Alderson MR. Mtb-reactive CD+ T lymphocytes: the relative contribution of classical versus non-classical HLA restriction. J Immunol. 2000 Jul 15;165(2):925-30.
Dillon, D.C., M.R. Alderson, C.H. Day, T. Bement, A. Campos-Neto, Y.A.W. Skeiky, T. Vedvick, R. Badaro, S.G. Reed, and R.L. Houghton. 2000. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J. Clin. Microbiol. 38:3285-3290. PMCID: PMC87375
Coler, R.N., Y.A.W. Skeiky, P.J. Ovendale, T.S. Vedvick, L. Gervassi, J. Guderian, S. Jen, S.G. Reed, and A. Campos-Neto. 2000. Cloning of a Mycobacterium tuberculosis gene encoding a PPD protein that elicits strong tuberculosis specific delayed type hypersensitivity. J. Infect. Dis. 182:224-233.
Hendrickson, R.C., J.F. Douglass, L.D. Reynolds, P.D. McNeill, D. Carter, S.G. Reed, and R.L. Houghton. 2000. Mass Spectrometric identification of Mtb81: a novel serological marker for tuberculosis. J. Clin. Microbiol. 38:2354-2361.
Skeiky, Y.A.W., P.J. Ovendale, S. Jen, M.R. Alderson, D.C. Dillon, S. Smith, C.B. Wilson, I.M. Orme, S.G. Reed, and A. Campos-Neto. 2000. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 165:7140-7149.
Alderson, M.R., T. Bement, C.H. Day, L. Zhu, D. Molesh, Y.A.W. Skeiky, R. Coler, D.M. Lewinsohn, S.G. Reed, and D.C. Dillon. 2000. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4+ T cells. J. Exp. Med. 191:551-559.
PMCID: PMC2195809
Skeiky, Y.A.W., M.J. Lodes, J.A. Guderian, R. Mohamath, T. Bement, M.R. Alderson, and S.G. Reed. 1999. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. and Immun. 67:3998-4007.
Dillon, D., M.R. Alderson, C.H. Day, D. Lewinsohn , R. Coler, T. Bement, A. Campos-Neto, Y.A.W. Skeiky, I.M. Orme, S. Steen, W. Dalemans, R. Badaro, and S.G. Reed. 1999. Molecular characterization and human T cell responses to a member of a novel Mycobacterium tuberculosis Mtb39 gene family. Infect. and Immun. 67:2941-2950.
Coler R.N., Y.A.W. Skeiky, T. Vedvick, T. Bement, P. Ovendale, A. Campos-Neto, M.R. Alderson, and S.G. Reed. 1998. Molecular cloning and immunological reactivity of a novel low-molecular-mass antigen of Mycobacterium tuberculosis. J. Immunol. 161:2356-2364.
Webb, J.R., T.S. Vedvick, M.R. Alderson, J.A. Guderian, P.J. Ovendale, S.M. Johnson, S.G. Reed, and Y.A.W. Skeiky. 1998. Molecular cloning, expression and immunogenicity of MTB12, a novel low molecular weight secreted antigen of Mycobacterium tuberculosis. Infect. and Immun. 66:4208-4214.
Lewinsohn, D.M., M.R. Alderson, A.L. Briden, S.R. Riddell, S.G. Reed, and K.H. Grabstein. 1998. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen presenting cells. J. Exp. Med. 187:1633-1640.
PMCID: PMC2212289
|
